Green Dye 3 vs Recombinant Bovine Growth Hormone: which is worse?

What is Green Dye 3?

Green Dye 3 (Fast Green FCF) is a synthetic blue-green triarylmethane dye similar to Blue Dye 1. It produces a sea-green color and is among the least used certified US food dyes. Its chemical formula is C37H34N2Na2O10S3.

What is Recombinant Bovine Growth Hormone?

Recombinant bovine growth hormone (rBGH), also called recombinant bovine somatotropin (rBST), is a synthetically produced version of the naturally occurring cattle growth hormone, manufactured using genetically engineered E. coli bacteria. Injected into dairy cows, it increases milk production by 10-15%. It was FDA-approved in 1993 under the brand name Posilac (originally Monsanto, later Elanco).

Documented risks

Green Dye 3: Green Dye 3 has a limited safety database compared to other certified food dyes, partly due to its infrequent use. A 1981 NTP bioassay (Technical Report 27) found statistically significant increases in urinary bladder tumors in male mice at high doses. The FDA reviewed these findings and, as with Blue 2, concluded the doses far exceeded typical human dietary exposure. Green 3 is not approved in the EU — under the EU's positive list system, only specifically approved additives may be used. Since Green 3 is not on the positive list, it is effectively banned. EFSA has not conducted a formal re-evaluation because it is not authorized for EU use. Hypersensitivity reactions have been reported. Like other synthetic triarylmethane dyes, Green 3 may cause contact dermatitis. The FDA's April 2025 phase-out announcement includes Green 3 among the eight petroleum-based synthetic dyes to be removed from the US food supply. Its already limited use means this phase-out has minimal market impact compared to Red 40 or Yellow 5.

Recombinant Bovine Growth Hormone: The central human health concern is that rBGH treatment significantly elevates insulin-like growth factor 1 (IGF-1) levels in treated cows' milk. IGF-1 is a naturally occurring growth hormone that promotes cell growth and division. Multiple epidemiological studies have associated elevated blood IGF-1 levels with increased cancer risk in humans. A 1998 study in The Lancet (Hankinson et al.) found that women with the highest IGF-1 blood levels had approximately 7 times the breast cancer risk compared to those with the lowest levels. A 2004 meta-analysis in JNCI (the Journal of the National Cancer Institute) confirmed significant associations between high IGF-1 levels and breast, prostate, and colorectal cancer risk. The mechanistic question is whether consuming rBGH-treated milk raises blood IGF-1 levels in humans. The FDA and WHO/FAO Codex Alimentarius concluded that IGF-1 in milk is a protein largely digested in the GI tract before absorption. Canadian regulatory researchers challenged this, arguing that pasteurization reduces proteases that would otherwise break down IGF-1, potentially allowing more intact IGF-1 to survive digestion. The Codex Alimentarius Commission made history in 1999 by declining to endorse rBST safety maximum residue limits — a split vote (33 in favor of the MRL, 29 against, with abstentions) demonstrating fundamental international disagreement. This is one of very few cases where Codex failed to establish a safety standard. Animal welfare is a second major concern: Health Canada's comprehensive 1999 review found that rBGH-treated cows had 25% higher rates of clinical mastitis, 50% higher lameness risk, increased reproductive problems, and shortened productive lifespans, requiring substantially more antibiotic treatment — an antibiotic resistance concern. Canada rejected rBGH approval in 1999 after its scientific review; the EU banned it in 1999.